'Neglected' public sector unlikely to benefit from Indian procurement plan
This article was originally published in Scrip
India's renewed policy to procure 103 drugs from Central Public Sector Enterprises (CPSEs), few of which are in good health, is unlikely dramatically to revive the fortunes of these firms, according to a clutch of industry experts.
You may also be interested in...ï»¿
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.